Single and combined IL28B, ITPA and SLC28A3 host genetic markers modulating response to anti-hepatitis C therapy

Pharmacogenomics

Volumn 12, Issue 12, 2011, Pages 1729-1740

  Lötsch, Jörn ^a   Hofmann, Wolf Peter ^a   Schlecker, Christina ^a   Zeuzem, Stefan ^a   Geisslinger, Gerd ^a   Ultsch, Alfred ^a   Doehring, Alexandra ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

hepatitis C; IL28B; ITPA; peginterferon; pharmacogenomics; ribavirin; SLC28A3; therapy success

Indexed keywords

GAMMA INTERFERON; NUCLEOSIDE; PEGINTERFERON ALPHA; RIBAVIRIN;

ACCURACY; ALLELE; ANEMIA; ARTICLE; ETHNICITY; GENE; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HEMOLYSIS; HEPATITIS C; HUMAN; IL28B GENE; ITPA GENE; PHARMACOGENOMICS; PREDICTION; SENSITIVITY AND SPECIFICITY; SLC28A3 GENE; TREATMENT RESPONSE; VIROLOGY;

ALLELES; BIOMARKERS, PHARMACOLOGICAL; DRUG RESISTANCE, MULTIPLE, VIRAL; GENETIC ASSOCIATION STUDIES; GENOTYPE; HAPLOTYPES; HEMOLYSIS; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MEMBRANE TRANSPORT PROTEINS; POLYETHYLENE GLYCOLS; PYROPHOSPHATASES; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 82255196200     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.99     Document Type: Article

References (93)

1. Afdhal NH, McHutchison JG, Zeuzem S et al. Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology 53 (1), 336-345 (2011).
2. Sheppard P, Kindsvogel W, Xu W et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 4 (1), 63-68 (2003). (Pubitemid 36104710)
3. Suppiah V, Moldovan M, Ahlenstiel G et al. IL28B is associated with response to chronic hepatitis C interferon-a and ribavirin therapy. Nat. Genet. 41 (10), 1100-1104 (2009).
4. Thomas DL, Thio CL, Martin MP et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461 (7265), 798-801 (2009).
5. Tanaka Y, Nishida N, Sugiyama M et al. Genome-wide association of IL28B with response to pegylated interferon-a and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41 (10), 1105-1109 (2009).
6. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461 (7262), 399-401 (2009).
7. Manolio TA. Genomewide association studies and assessment of the risk of disease. N. Engl. J. Med. 363 (2), 166-176 (2010).
8. Spencer CC, Su Z, Donnelly P, Marchini J. Designing genome-wide association studies: sample size, power, imputation, and the choice of genotyping chip. PLoS Genet. 5 (5), e1000477 (2009).
9. Li M, Liu X, Zhou Y, Su SB. Interferon-l: the modulators of antivirus, antitumor, and immune responses. J. Leukoc. Biol. 86 (1), 23-32 (2009).
10. NIH: National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C. Hepatology 36 (5 Suppl. 1), S3-S20 (2002).
11. Munir S, Saleem S, Idrees M et al. Hepatitis C treatment: current and future perspectives. Virol. J. 7, 296 (2010).
12. Lemon SM, McKeating JA, Pietschmann T et al. Development of novel therapies for hepatitis C. Antiviral. Res. 86 (1), 79-92 (2010).
13. Lin S, McLennan AG, Ying K et al. Cloning, expression, and characterization of a human inosine triphosphate pyrophosphatase encoded by the itpa gene. J. Biol. Chem. 276 (22), 18695-18701 (2001).
14. Fellay J, Thompson AJ, Ge D et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 464 (7287), 405-408 (2010).
15. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 36 (5Suppl. 1), S237-S244 (2002). (Pubitemid 35253486)
16. Russmann S, Grattagliano I, Portincasa P, PalmieriVO, Palasciano G. Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. Curr. Med. Chem. 13 (27), 3351-3357 (2006). (Pubitemid 44669779)
17. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon a-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347 (13), 975-982 (2002).
18. Hadziyannis SJ, Sette H Jr, Morgan TR et al. Peginterferon-a2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140 (5), 346-355 (2004).
19. Hezode C, Forestier N, Dusheiko G et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 360 (18), 1839-1850 (2009).
20. Doehring A, Hofmann WP, Schlecker C et al. Role of nucleoside transporters SLC28A2/3 and SLC29A1/2 genetics in ribavirin therapy: protection against anemia in patients with chronic hepatitis C. Pharmacogenet. Genomics 21 (5), 289-296 (2011).
21. Ritzel MW, Ng AM, Yao SY et al. Molecular identification and characterization of novel human and mouse concentrative Na+-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). J. Biol. Chem. 276 (4), 2914-2927 (2001).
22. Lötsch J, Flühr K, Neddermayer T, Doehring A, Geisslinger G. The consequence of concomitantly present functional genetic variants for the identification of functional genotype-phenotype associations in pain. Clin. Pharmacol. Ther. 85 (1), 25-30 (2009).
23. Ank N, West H, Paludan SR. IFN-l: novel antiviral cytokines. J. Interferon. Cytokine Res. 26 (6), 373-379 (2006).
24. Doyle SE, Schreckhise H, Khuu-Duong K et al. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 44 (4), 896-906 (2006). (Pubitemid 46489554)
25. Hong SH, Cho O, Kim K, Shin HJ, Kotenko SV, Park S. Effect of interferon-l on replication of hepatitis B virus in human hepatoma cells. Virus Res. 126 (1-2), 245-249 (2007). (Pubitemid 46726717)
26. Marcello T, Grakoui A, Barba-Spaeth G et al. Interferons a and l inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131 (6), 1887-1898 (2006). (Pubitemid 44958521)
27. Robek MD, Boyd BS, Chisari FV. l interferon inhibits hepatitis B and C virus replication. J. Virol. 79 (6), 3851-3854 (2005). (Pubitemid 40327973)
28. Mihm S, Frese M, Meier V et al. Interferon type I gene expression in chronic hepatitis C. Lab. Invest. 84 (9), 1148-1159 (2004). (Pubitemid 39128260)
29. Rauch A, Kutalik Z, Descombes P et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138 (4), 1338-1345, 1345.e1-e7 (2010).
30. Dring MM, Morrison MH, McSharry BP et al. Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection. Proc. Natl Acad. Sci. USA 108 (14), 5736-5741 (2011).
31. Rallon NI, Naggie S, Benito JM et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 24 (8), F23-F29 (2010).
32. Lange CM, Moradpour D, Doehring A et al. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J. Hepatol. 55 (2), 322-327 (2010).
33. Labarga P, Soriano V, Caruz A et al. Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients. AIDS 25 (6), 761-766 (2011).
34. Moghaddam A, Melum E, Reinton N et al. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology 53 (3), 746-754 (2011).
35. Sarrazin C, Susser S, Doehring A et al. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J. Hepatol. 54 (3), 415-421 (2011).
36. Honda M, Sakai A, Yamashita T et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 139 (2), 499-509 (2010).
37. Chen L, Borozan I, Feld J et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128 (5), 1437-1444 (2005). (Pubitemid 40712193)
38. Lotrich FE, Loftis JM, Ferrell RE, Rabinovitz M, Hauser P. IL28B polymorphism is associated with both side effects and clearance of hepatitis C during interferon-A therapy. J. Interferon Cytokine Res. doi:10.1089/jir.2010. 0074 (2010) (Epub ahead of print).
39. Page T, Connor JD. The metabolism of ribavirin in erythrocytes and nucleated cells. Int. J. Biochem. 22 (4), 379-383 (1990). (Pubitemid 20158850)
40. De Franceschi L, Fattovich G, Turrini F et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 31 (4), 997-1004 (2000). (Pubitemid 30169949)
41. Ibarra KD, Pfeiffer JK. Reduced ribavirin antiviral efficacy via nucleoside transporter-mediated drug resistance. J. Virol. 83 (9), 4538-4547 (2009).
42. Govindarajan R, Endres CJ, Whittington D et al. Expression and hepatobiliary transport characteristics of the concentrative and equilibrative nucleoside transporters in sandwich-cultured human hepatocytes. Am. J. Physiol. Gastrointest. Liver Physiol. 295 (3), G570-G580 (2008).
43. Hitomi Y, Cirulli ET, Fellay J et al. Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by restoring adenylosuccinate synthase function. Gastroenterology 140 (4), 1314-1321 (2011).
44. Sumi S, Marinaki AM, Arenas M et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum. Genet. 111 (4-5), 360-367 (2002). (Pubitemid 36075062)
45. Thompson AJ, Fellay J, Patel K et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology 139 (4), 1181-1189 (2010).
46. Sakamoto N, Tanaka Y, Nakagawa M et al. ITPA gene variant protects against anemia induced by pegylated interferon-a and ribavirin therapy for Japanese patients with chronic hepatitis C. Hepatol. Res. 40 (11), 1063-1071 (2010).
47. Thompson AJ, Santoro R, Piazzolla V et al. Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. Hepatology 53 (2), 389-395 (2011).
48. Costa JM, Telehin D, Munteanu M et al. HCV-GenoFibrotest: a combination of viral, liver and genomic (IL28b, ITPA, UGT1A1) biomarkers for predicting treatment response in patients with chronic hepatitis C. Clin. Res. Hepatol. Gastroenterol. 35 (3), 204-213 (2011).
49. Azakami T, Hayes CN, Sezaki H et al. Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy. J. Med. Virol. 83 (6), 1048-1057 (2011).
50. Ochi H, Maekawa T, Abe H et al. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy-a genome-wide study of Japanese HCV virus patients. Gastroenterology 139 (4), 1190-1197 (2010).
51. Suzuki F, Suzuki Y, Akuta N et al. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology 53 (2), 415-421 (2011).
52. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138 (2), 447-462 (2010).
53. Vitali SH, Randolph AG. Assessing the quality of case-control association studies on the genetic basis of sepsis. Pediatr. Crit. Care Med. 6 (Suppl. 3), S74-S77 (2005). (Pubitemid 40724256)
54. Arenas M, Duley J, Sumi S, Sanderson J, Marinaki A. The ITPA c.94C〉A and g.IVS2+21A〉C sequence variants contribute to missplicing of the ITPA gene. Biochim.Biophysic. Acta 1772 (1), 96-102 (2007). (Pubitemid 44960729)
55. Herting G, Barber K, Zappala MR, CunninghamRP, Burgis NE. Quantitative invitro and invivo characterization of the human P32T mutant ITPase. Biochim. Biophys. Acta 1802 (2), 269-274 (2010).
56. Stepchenkova EI, Tarakhovskaya ER, Spitler K et al. Functional study of the P32T ITPA variant associated with drug sensitivity in humans. J. Mol. Biol. 392 (3), 602-613 (2009).
57. Heller T, Oellerich M, Armstrong VW, von Ahsen N. Rapid detection of ITPA 94C〉A and IVS2 + 21A〉C gene mutations by real-time fluorescence PCR and invitro demonstration of effect of ITPA IVS2 + 21A〉C polymorphism on splicing efficiency. Clin. Chem. 50 (11), 2182-2184 (2004). (Pubitemid 39425868)
58. Urban TJ, Thompson AJ, Bradrick SS et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 52 (6), 1888-1896 (2010).
59. Welzel TM, Morgan TR, Bonkovsky HL et al. Variants in interferon-a pathway genes and response to pegylated interferon-A2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology 49 (6), 1847-1858 (2009).
60. Chung RT, Gale M Jr, Polyak SJ et al. Mechanisms of action of interferon and ribavirin in chronic hepatitis C: summary of a workshop. Hepatology 47 (1), 306-320 (2008). (Pubitemid 351171068)
61. Knapp S, Yee LJ, Frodsham AJ et al. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun. 4 (6), 411-419 (2003). (Pubitemid 38967606)
62. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor a promoter on transcriptional activation. Proc. Natl Acad. Sci. USA 94 (7), 3195-3199 (1997). (Pubitemid 27157287)
63. Suzuki F, Arase Y, Suzuki Y et al. Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection. J. Viral. Hepatitis 11 (3), 271-276 (2004). (Pubitemid 38658454)
64. Hijikata M, Ohta Y, Mishiro S. Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt-88) correlated with the response of hepatitis C patients to interferon. Intervirology 43 (2), 124-127 (2000).
65. Edwards-Smith CJ, Jonsson JR, Purdie DM, Bansal A, Shorthouse C, Powell EE. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon a. Hepatology 30 (2), 526-530 (1999). (Pubitemid 29357520)
66. Mueller T, Gessner R, Sarrazin C et al. Apolipoprotein E4 allele is associated with poor treatment response in hepatitis C virus (HCV) genotype 1. Hepatology (Letter) 38 (6), 1592, author reply 1593 (2003).
67. Bonkovsky HL, Naishadham D, Lambrecht RW et al. Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology 131 (5), 1440-1451 (2006). (Pubitemid 44780862)
68. Hardy GH. Mendelian proportions in a mixed population. Science 28, 49-50 (1908).
69. Akuta N, Suzuki F, Hirakawa M et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 52 (2), 421-429 (2010).
70. Jacobson IM, Catlett I, Marcellin P et al. Telaprevir substantially improved SVR rates across all IL28B genotypes in the advance trial. J. Hepatol. 54, S542-S543 (2011).
71. Pol S, Aerssens J, Zeuzem S et al. Similar SVR rates in IL28B CC, CT or TT prior relapser partial-or null-responder patients treated with telaprevir/peginterferon/ribavirin: retrospective analysis of the realize study. J. Hepatol. 54, S6-S7 (2011).
72. Poordad F, Bronowicki JP, Gordon SC et al. IL28B polymorphism predicts virologic response in patients with hepatitis C genotype 1 treated with boceprevir (boc) combination therapy. J. Hepatol. 54, S6 (2011).
73. Sakamoto N, Nakagawa M, Tanaka Y et al. Association of IL28B variants with response to pegylated-interferon a plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b. J. Med. Virol. 83 (5), 871-878 (2011).
74. Chen JY, Lin CY, Wang CM et al. IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-a plus ribavirin therapy in Taiwanese chronic HCV infection. Genes Immun. 12 (4), 300-309 (2011).
75. Hsu CS, Hsu SJ, Chen HC et al. Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. Proc. Natl Acad. Sci. USA 108 (9), 3719-3724 (2011).
76. Nattermann J, Vogel M, Nischalke HD et al. Genetic variation in IL28B and treatment-induced clearance of hepatitis C virus in HIV-positive patients with acute and chronic hepatitis C. J. Infect. Dis. 203 (5), 595-601 (2011).
77. Charlton MR, Thompson A, Veldt BJ et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 53 (1), 317-324 (2011).
78. Darling JM, Aerssens J, Fanning G et al. Quantitation of pretreatment serum interferon-g-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology 53 (1), 14-22 (2011).
79. Yu ML, Huang CF, Huang JF et al. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 53 (1), 7-13 (2011).
80. Doehring A, Hofmann WP, Schlecker C et al. Screening for IL28B gene variants identifies predictors of hepatitis C therapy success. Antivir. Ther. 15 (8), 1099-1106 (2010).
81. Scherzer TM, Hofer H, Staettermayer AF et al. Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon a-2a and ribavirin. J. Hepatol. 54 (5), 866-871 (2011).
82. Dill MT, Duong FH, Vogt JE et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 140 (3), 1021-1031 (2011).
83. Clausen LN, Weis N, Astvad K et al. Interleukin-28B polymorphisms are associated with hepatitis C virus clearance and viral load in a HIV-1-infected cohort. J. Viral Hepat. 18 (4), e66-e74 (2011).
84. Hayes CN, Kobayashi M, Akuta N et al. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut 60 (2), 261-267 (2011).
85. Medrano J, Neukam K, Rallon N et al. Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV. Clin. Infect. Dis. 51 (10), 1209-1216 (2010).
86. Pineda JA, Caruz A, Rivero A et al. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin. Infect. Dis. 51 (7), 788-795 (2010).
87. Grebely J, Petoumenos K, Hellard M et al. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology 52 (4), 1216-1224 (2010).
88. Stattermayer AF, Stauber R, Hofer H et al. Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C. Clin. Gastroenterol. Hepatol. 9 (4), 344-350.e2 (2011).
89. Fukuhara T, Taketomi A, Motomura T et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 139 (5), 1577-1585, 1585.e1-e3 (2010).
90. Tillmann HL, Thompson AJ, Patel K et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 139 (5), 1586-1592, 1592.e1 (2010).
91. Mangia A, Thompson AJ, Santoro R et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 139 (3), 821-827, 827.e1 (2010).
92. McCarthy JJ, Li JH, Thompson A et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 138 (7), 2307-2314 (2010).
93. den Dunnen JT, Antonarakis SE. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum. Mutat. 15 (1), 7-12 (2000). (Pubitemid 30036162)